RxDoctor Payments DataLook up a doctor →

Jonathan Barnes

Nurse Practitioner · Columbia, MONPI 1376915678

Payments from drug & device makers

$10,300in general payments, 2019–2025

Across 537 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$881
  • Regeneron Healthcare Solutions, Inc.$828
  • Sanofi$750
  • Genentech USA, Inc.$631
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,22099%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,300 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$62,456
Medicare patients
314
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter293$227,015
Breztri AerosphereBudesonide/Glycopyr/Formoterol86$77,277
Breo ElliptaFluticasone/Vilanterol111$54,599
Spiriva RespimatTiotropium Bromide70$45,216
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$25,964
SymbicortBudesonide/Formoterol Fumarate89$22,644
Combivent RespimatIpratropium/Albuterol Sulfate32$20,691
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$16,292
Incruse ElliptaUmeclidinium Bromide29$13,180
Advair HfaFluticasone Propion/Salmeterol32$11,630
DuleraMometasone/Formoterol25$10,941
Arnuity ElliptaFluticasone Furoate31$8,125
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$7,012
Albuterol Sulfate HfaAlbuterol Sulfate261$6,404
ArexvyRsvpref3 Antigen/As01e/Pf19$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,010$334,144538 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,484$99,921175 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$881$82,200131 claims
MerckDulera$103$10,94125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →